153 related articles for article (PubMed ID: 34755248)
1. Value of Primary Rectal Tumor PET/MRI in the Prediction of Synchronic Metastatic Disease.
Queiroz MA; Ortega CD; Ferreira FR; Capareli FC; Nahas SC; Cerri GG; Buchpiguel CA
Mol Imaging Biol; 2022 Jun; 24(3):453-463. PubMed ID: 34755248
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic accuracy of FDG-PET/MRI versus pelvic MRI and thoracic and abdominal CT for detecting synchronous distant metastases in rectal cancer patients.
Queiroz MA; Ortega CD; Ferreira FR; Nahas SC; Cerri GG; Buchpiguel CA
Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):186-195. PubMed ID: 32561971
[TBL] [Abstract][Full Text] [Related]
3. PET/MRI Characterization of Mucinous Versus Nonmucinous Components of Rectal Adenocarcinoma: A Comparison of Tumor Metabolism and Cellularity.
Queiroz MA; Naves A; Dreyer PR; Cerri GG; Buchpiguel CA
AJR Am J Roentgenol; 2021 Feb; 216(2):376-383. PubMed ID: 33295813
[No Abstract] [Full Text] [Related]
4. Feasibility of [18F]FDG PET/MRI with Early-Delayed and Extended PET as One-Stop Imaging for Staging and Predicting Metastasis in Rectal Cancer.
Seto S; Tsujikawa T; Sawai K; Kurebayashi H; Morikawa M; Okazawa H; Goi T
Oncology; 2022; 100(4):212-220. PubMed ID: 35086111
[TBL] [Abstract][Full Text] [Related]
5. Initial M Staging of Rectal Cancer: FDG PET/MRI with a Hepatocyte-specific Contrast Agent versus Contrast-enhanced CT.
Yoon JH; Lee JM; Chang W; Kang HJ; Bandos A; Lim HJ; Kang SY; Kang KW; Ryoo SB; Jeong SY; Park KJ
Radiology; 2020 Feb; 294(2):310-319. PubMed ID: 31793850
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic performance of
Hotta M; Minamimoto R; Yano H; Gohda Y; Shuno Y
Cancer Imaging; 2018 Jan; 18(1):4. PubMed ID: 29378659
[TBL] [Abstract][Full Text] [Related]
7. The potential predictive value of MRI and PET-CT in mucinous and nonmucinous rectal cancer to identify patients at high risk of metastatic disease.
Barbaro B; Leccisotti L; Vecchio FM; Di Matteo M; Serra T; Salsano M; Poscia A; Coco C; Persiani R; Alfieri S; Gambacorta MA; Valentini V; Giordano A; Bonomo L
Br J Radiol; 2017 Jan; 90(1069):20150836. PubMed ID: 27845566
[TBL] [Abstract][Full Text] [Related]
8. Added value of quantitative, multiparametric 18F-FDG PET/MRI in the locoregional staging of rectal cancer.
Herold A; Wassipaul C; Weber M; Lindenlaub F; Rasul S; Stift A; Stift J; Mayerhoefer ME; Hacker M; Ba-Ssalamah A; Haug AR; Tamandl D
Eur J Nucl Med Mol Imaging; 2022 Dec; 50(1):205-217. PubMed ID: 36063201
[TBL] [Abstract][Full Text] [Related]
9. Value of combined multiparametric MRI and FDG-PET/CT to identify well-responding rectal cancer patients before the start of neoadjuvant chemoradiation.
Schurink NW; Min LA; Berbee M; van Elmpt W; van Griethuysen JJM; Bakers FCH; Roberti S; van Kranen SR; Lahaye MJ; Maas M; Beets GL; Beets-Tan RGH; Lambregts DMJ
Eur Radiol; 2020 May; 30(5):2945-2954. PubMed ID: 32034488
[TBL] [Abstract][Full Text] [Related]
10. Adverse features on rectal MRI identify a high-risk group that may benefit from more intensive preoperative staging and treatment.
Hunter CJ; Garant A; Vuong T; Artho G; Lisbona R; Tekkis P; Abulafi M; Brown G
Ann Surg Oncol; 2012 Apr; 19(4):1199-205. PubMed ID: 21913017
[TBL] [Abstract][Full Text] [Related]
11. 18F-FDG PET/MRI for Rectal Cancer TNM Restaging After Preoperative Chemoradiotherapy: Initial Experience.
Crimì F; Spolverato G; Lacognata C; Garieri M; Cecchin D; Urso ED; Zucchetta P; Pucciarelli S; Pomerri F
Dis Colon Rectum; 2020 Mar; 63(3):310-318. PubMed ID: 31842163
[TBL] [Abstract][Full Text] [Related]
12. Staging of neuroendocrine tumours: comparison of [⁶⁸Ga]DOTATOC multiphase PET/CT and whole-body MRI.
Schraml C; Schwenzer NF; Sperling O; Aschoff P; Lichy MP; Müller M; Brendle C; Werner MK; Claussen CD; Pfannenberg C
Cancer Imaging; 2013 Mar; 13(1):63-72. PubMed ID: 23466785
[TBL] [Abstract][Full Text] [Related]
13. Comparison of nodal staging between CT, MRI, and [
Morawitz J; Bruckmann NM; Dietzel F; Ullrich T; Bittner AK; Hoffmann O; Ruckhäberle E; Mohrmann S; Häberle L; Ingenwerth M; Abrar DB; Sawicki LM; Breuckmann K; Fendler WP; Herrmann K; Buchbender C; Antoch G; Umutlu L; Kirchner J
Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):992-1001. PubMed ID: 34476552
[TBL] [Abstract][Full Text] [Related]
14. The role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the primary staging of rectal cancer.
Ozis SE; Soydal C; Akyol C; Can N; Kucuk ON; Yagcı C; Erkek AB; Kuzu MA
World J Surg Oncol; 2014 Feb; 12():26. PubMed ID: 24484935
[TBL] [Abstract][Full Text] [Related]
15. Comparison of
Sarabhai T; Schaarschmidt BM; Wetter A; Kirchner J; Aktas B; Forsting M; Ruhlmann V; Herrmann K; Umutlu L; Grueneisen J
Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):67-76. PubMed ID: 28840302
[TBL] [Abstract][Full Text] [Related]
16. Preoperative staging of non-small-cell lung cancer: comparison of whole-body diffusion-weighted magnetic resonance imaging and 18F-fluorodeoxyglucose-positron emission tomography/computed tomography.
Sommer G; Wiese M; Winter L; Lenz C; Klarhöfer M; Forrer F; Lardinois D; Bremerich J
Eur Radiol; 2012 Dec; 22(12):2859-67. PubMed ID: 22772365
[TBL] [Abstract][Full Text] [Related]
17. What is the diagnostic performance of 18-FDG-PET/MR compared to PET/CT for the N- and M- staging of breast cancer?
Botsikas D; Bagetakos I; Picarra M; Da Cunha Afonso Barisits AC; Boudabbous S; Montet X; Lam GT; Mainta I; Kalovidouri A; Becker M
Eur Radiol; 2019 Apr; 29(4):1787-1798. PubMed ID: 30267154
[TBL] [Abstract][Full Text] [Related]
18. Metabolic Tumor Volume on 18F-FDG PET/CT Improves Preoperative Identification of High-Risk Endometrial Carcinoma Patients.
Husby JA; Reitan BC; Biermann M; Trovik J; Bjørge L; Magnussen IJ; Salvesen ØO; Salvesen HB; Haldorsen IS
J Nucl Med; 2015 Aug; 56(8):1191-8. PubMed ID: 26045311
[TBL] [Abstract][Full Text] [Related]
19. Preoperative 18F-FDG PET/CT tumor markers outperform MRI-based markers for the prediction of lymph node metastases in primary endometrial cancer.
Fasmer KE; Gulati A; Dybvik JA; Ytre-Hauge S; Salvesen Ø; Trovik J; Krakstad C; Haldorsen IS
Eur Radiol; 2020 May; 30(5):2443-2453. PubMed ID: 32034487
[TBL] [Abstract][Full Text] [Related]
20. Complementary Prognostic Value of Pelvic Magnetic Resonance Imaging and Whole-Body Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in the Pretreatment Assessment of Patients With Cervical Cancer.
Sala E; Micco M; Burger IA; Yakar D; Kollmeier MA; Goldman DA; Gonen M; Park KJ; Abu-Rustum NR; Hricak H; Vargas HA
Int J Gynecol Cancer; 2015 Oct; 25(8):1461-7. PubMed ID: 26397068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
